Bibliography
- Vogel CL , CobleighMA, TripathyDet al. : Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.J. Clin. Oncol.20, 719–726 (2002).
- O‘Dwyer ME , DrukerBJ: STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia.Lancet Oncol.1, 207–211 (2000).
- Ross JS , GinsburgGS: Integrating diagnostics and therapeutics: revolutionizing drug discovery and patient care.Drug Discov. Today7(16), 859–864 (2002).
- Ross JS , SchenkeinDP, PietruskoRet al. : Targeted therapies for cancer 2004.Am. J. Clin. Pathol.122(4), 598–609 (2004).
- Davies EC , GreenCF, TaylorS, WilliamsonPR, MottramDR, PirmohamedM: Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes.PLoS One4(2), e4439 (2009).
- Wilke RA , LinDW, RodenDM: Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.Nat. Rev. Drug Discov.6(11), 904–916 (2007).
- Ginsburg GS , McCarthyJJ: Personalized medicine: revolutionizing drug discovery and patient care.Trends Biotechnol.19, 491–496 (2001).
- Waters MD , FostelJM: Toxicogenomics and systems toxicology: aims and prospects.Nat. Rev. Genet.5(12), 936-948 (2004).
- Monzon FA , OginoS, HammondMEet al. : The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer.Arch. Pathol. Lab. Med.133, 1600–1606 (2009).
- Sequist LV , JoshiVA, JännePAet al. : Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.Oncologist12, 90–98 (2007).
- Gerber DE , MinnaJD: ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.Cancer Cell18, 548–551 (2010).
- Smalley KS : PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.Curr. Opin. Investig. Drugs11, 699–706 (2010).
- Macconaill LE , GarrawayLA: Clinical implications of the cancer genome.J. Clin. Oncol.28(35), 5219–5228 (2010).
- Schilsky RL , AllenJ, BennerJ, SigalE, McClellanM: Commentary: tackling the challenges of developing targeted therapies for cancer.Oncologist15(5), 484–487 (2010).